MTSR Total Utang marang Modal Metsera Therapeutics

Lambang korporat lan logo Metsera Inc (MTSR)

The current share price of Metsera Inc (MTSR) plotted on this chart demonstrates a debt-to-equity ratio of 0.01. The operating model relies on external contractors for the production of biologics, which is offset by strict quality oversight. Management's strategy focuses on developing convenient, long-acting medications. Consequently, Metsera Inc (MTSR) is creating innovative peptide therapies capable of transforming the approach to obesity treatment.

MTSR: Total Utang marang Modal Metsera 01.02.2025 - 29.11.2025

Rincian analitis lan laporan data perusahaan Metsera Therapeutics (MTSR)

- rega lan prakiraan konsensus rega:
Bagan rega Metsera|MTSR - Bagan tingkat prakiraan
- data kapitalisasi pasar:
Kapitalisasi pasar Metsera|MTSR - Nilai Dipunlarasaken Utang lan Kas
- data kapitalisasi buku:
Nilai Buku saben Saham Metsera|MTSR - Kapitalisasi Buku|Rasio Nilai Pasar marang Nilai Buku metsera.com|MTSR - Nilai Agregat Aset
- data utang lan likuiditas:
Utang marang Ekuitas Metsera Inc|MTSR - Rasio utang jangka dawa marang ekuitas|Utang jangka cendhak marang modal Metsera Inc|MTSR - Gunggung utang perusahaan|Utang marang nilai buku Metsera
Analisis komprehensif perusahaan:MTSR - Metsera
Produk merek Metsera Therapeutics

This indicator is calculated as the ratio of total liabilities to the market value of equity, measuring the business's degree of reliance on debt financing. On the GURU.Markets platform, the total debt-to-equity ratio allows for an assessment of the financial stability of Metsera Inc. (MTSR) amid a lack of revenue and high costs associated with the final stages of clinical drug trials.

Pesaing wigati

Utang marang Ekuitas Ascendis Pharma ASND|Utang Agregat marang Ekuitas Madrigal Pharmaceuticals Inc|Corcept (CORT) - Total Utang marang Modal|Rasio Kabeh Utang marang Dana Pribadi Rhythm Corp (RYTM)|Total Utang marang Modal AKRO (Akero Therapeutics)|moonlaketx.com - Total Utang marang Modal|Utang marang Ekuitas Crinetics (CRNX)|NAMS: Rasio Kabeh Utang marang Dana Pribadi|SLNO (Soleno) - Utang marang Ekuitas|Amicus Corp (FOLD) - Rasio Total Utang marang Ekuitas|ETNB (89bio, Inc.) - Total Utang marang Modal|Total Utang marang Modal agios.com (AGIO)|Structure Therapeutics Inc. (GPCR) - Rasio Total Utang marang Ekuitas|Rasio Kabeh Utang marang Dana Pribadi MDXG (MiMedx Group Inc)|Rezolute Corp - Utang marang Ekuitas|Rasio Total Utang marang Ekuitas Lexicon Corp LXRX|MBX (MBX Biosciences Inc) - Total Utang marang Modal|altimmune.com (ALT) - Utang marang Modal|AARD - Rasio Total Utang marang Ekuitas|Sagimet Biosciences, Inc. (SGMT) - Utang Agregat marang Modal|BIOA (BioAge Labs Inc.) - Total Utang marang Modal|Total Utang marang Modal Biomea Fusion Corp|Total Utang marang Modal Quince Therapeutics (QNCX)|Utang marang Ekuitas GUTS (fractyl.com)|VTVT: Utang marang Ekuitas|Agape ATP Corp - Utang marang Modal|PLUR - Utang marang Ekuitas|SYBX - Utang marang Ekuitas|Lipocine Inc. - Total Utang marang Modal|MTNB (Matinas BioPharma Holdings) - Koefisien Total Utang marang Modal|SPRB: Utang marang Ekuitas|Koefisien Total Utang marang Modal GLTO|Utang marang Ekuitas CTCX (Carmell Corp)|Rasio Total Utang marang Ekuitas LUMO (Lumos Therapeutics)|Organovo Holdings, Inc. - Utang marang Ekuitas|Rasio Total Utang marang Ekuitas radiuspharm.com RDUS